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Abstract 
Purpose 
The diagnosis of cancer is often prolonged in teenagers and young adults (TYA). 
There may be lessons in improving this from international comparisons. However, 
international studies are complex and so we conducted a pilot study to examine the 
key barriers to large-scale research in this field.  
Methods 
We provided translated questionnaires covering key aspects of presentation and 
clinical management within 60 days of a confirmed cancer diagnosis, to patients 
aged 13-29 years inclusive, to their primary care physicians and to the cancer 
specialists managing their cancer. We conducted descriptive analyses of the data 
and also the process of study implementation.  
Results 
For our pilot, collecting triangulated data was feasible but varying regulatory 
requirements and professional willingness to contribute data were key barriers. The 
time of data collection and the method for collecting symptom reports were important 
for timely and accurate data synthesis. Patients reported more symptoms than 
professionals recorded. We observed substantial variation in pathways to cancer 
diagnosis to explore definitively in future studies.  
Conclusion 
4 
4 
Focussed research upon the mechanisms underpinning complex cancer pathways, 
and focussing that research upon specific cancer types within TYA may be the key 
next areas of study.  
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Background 
Cancer is a substantial cause of morbidity and mortality in teenagers and young adults 
(TYA) [1, 2]. The incidence in Europe over the last decade is approximately 20 and 28 
per 100,000 person years for 15-19 and 20-24 year olds respectively [3] [4],[5]. 
European data show an annual average incidence increase of 1.5-2.0% [6-9]. TYA 
with many cancers have poorer outcomes compared to younger children and several 
have poorer outcomes than older adults [10-13]. European survival rates after TYA 
cancers vary by geographical region, age group, gender, and cancer type [14, 15].  
There is low awareness of cancer during adolescence and early adulthood, in the 
public and providers and healthcare professionals may not immediately recognise 
TYA cancer symptoms [16-19]. Therefore, when TYA develop cancer, they may 
experience a longer time until diagnosis and treatment than younger children or older 
adults [20-24]. In general, cancers that are more advanced when commencing 
treatment have poorer outcomes whether due to requiring more treatment (causing 
greater late toxicity), or through lower treatment success rates and  studying and 
understanding the time to diagnosis is an important TYA cancer research goal [17, 
25]. While some studies show a direct correlation, the relation between symptom 
interval and outcome is complex with clinical, biological and human factors involved. 
[20, 23]. [16-19]. Access to primary care maybe relevant and health insurance is 
sometimes relevant [19, 21, 26]. In a large UK primary care cohort study, in the 3 
months before diagnosis 42.9% of TYA with cancer consulted primary care  times 
vs 11.5% in age-matched patients without a cancer diagnosis [27]. Almost twice as 
many TYA visited their GP more than 3 times before diagnosis of cancer than is 
observed in older adults (38% versus 20%) [28].  
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Understanding international variation in time to diagnosis could assist us in improving 
outcomes; sharing of best practice and adhering to consistent research definitions [29, 
30]. Previous and ongoing TYA studies do not allow valid international comparisons 
or identify where long times to diagnosis may be occurring [17, 31]. The international 
cancer benchmarking project (ICBP) module 4 examined the route from symptoms to 
cancer treatment in adults and their clinicians [31-33]. 
Co-operation over large geographical areas and large datasets are required to reach 
robust research findings particularly given the relatively rarity of  AYA cancers [34]. 
This requires co-operation, infrastructure and funding. International clinical networks 
and online data capture may overcome some of these barriers, but introduce others. 
Within the EU FP7 grant µ(XURSHDQ Network for Cancer in Children and Adolescents 
(1&&$¶ between 2011 and 2016, an international collaborative working group of 
clinicians, researchers and patients in TYA cancer was initiated. As an initial step to 
developing formal research proposals, the group developed a pilot study as a test case 
for future larger scale collaborative research. This was undertaken without study 
management funding but based upon the co-operation present within the network, to 
examine if this process  could minimise the need for full funding for future  studies.  
Study Objectives 
1. To pilot collaborative working and data collection within the European TYA 
cancer community 
2. To identify and characterise timescales within the diagnostic pathway of cancer 
in the TYA population 
3. To examine the consistency of report of waiting times, by the triangulation of 
the responses of patients with those of clinicians in different healthcare sectors. 
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Methods 
Investigators were approached through the ENCCA network of TYA professionals.  
Ethics and regulatory elements 
Ethics approval was obtained for the use of shared data collection, security and 
storage procedures, according to the various local and international regulations. The 
age range for inclusion in the whole project spanned 13-29 year olds although differed 
in some locations, so two different consent forms were designed: Those under 16 
years required both the consent of a parent/guardian and patient assent, whereas 
those over 16 years consented directly.  
 
Eligibility criteria 
Patients 
x Aged between 13 and 29 years on study entry 
x Diagnosed with leukaemia, sarcomas of bone or soft tissue, lymphomas, 
central nervous system tumours, germ cell tumours or carcinoma. 
x Was receiving or had received care in a contributing specialist centre.  
x Less than 60 days from cancer diagnosis.  
x Able to complete the questionnaire, with help from another person if necessary 
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Professionals  
x The oncology/haematology specialist involved in the care of the patient 
x The GP/community/ primary care doctor who initially saw the patient and/or 
made the referral to specialist services.  
These professionals were identified by the patient in their questionnaire. 
Questionnaires 
Questionnaires developed in the international cancer benchmarking project module 4 
[31, 32] were adapted by experienced cancer clinicians and the research team to 
better fit the TYA population. The questionnaires contained items related to symptoms, 
clinical contact/interventions and time periods. Three different versions were 
developed; for patients, oncology/haematology specialists and general practitioners 
(GP)/primary care physicians.  
 
Patient Questionnaire 
Each TYA participant was asked for limited demographic and clinical details, but no 
personally identifiable information was requested (Appendix 1).  
When the participant identified their specific diagnosis they then selected from a list of 
cancer symptoms compiled by experienced clinical study members, tailored to each 
cancer type and including free space to add other symptoms they experienced before 
their diagnosis. This aimed to focus upon relevant specific symptoms. The patient was 
also asked about events leading to diagnosis and to estimate dates of key events in 
their pathway including dates of first symptoms, referral, diagnosis and treatment.  
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Primary Care questionnaire 
The primary care FOLQLFLDQ¶V questionnaire documented the symptoms of their patient 
using free text to encourage wide reporting, as well as how many clinical assessments 
occurred in primary care. They were asked what investigations were ordered and 
when/how they referred the patient further. The research team wrote the information 
sheet to help GPs feel confident in participating, by explaining that that this research 
was not designed to criticise them or to imply any mistakes or delays, but to 
understand processes and compare perspectives when measuring previous events 
(see GP information sheet in Appendix 2). 
 
Specialist questionnaire 
The specialist questionnaire asked consultant oncologist/haematologists questions 
about how the patient was first referred to their service. They were also asked how the 
patient was diagnosed and the details of their diagnosis and treatment. Again, the 
information sheet emphasised there was no criticism or implication of delay. .  
 
Data collection 
A bespoke online system was developed for the data collection in this project, with a 
unique and secure login system for each participating country that could link SDWLHQWV¶ 
data to their GPs and specialists.  
 
The GPs and specialists had the same prefix as their patient, so that the data could 
be linked e.g. GB0101P would be linked with GB0101G and GB0101C. To access the 
system each participant was given a login card (see Appendix 1), for secure use on 
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the survey website to input their patient ID, authentication code and three grid 
references (e.g. A1, C5, H2). The grid references changed upon website access, 
enhancing data security.  
 
Development of the website took 5 months including piloting with 2 service users. The 
questionnaires were translated forwards from English into the different languages 
appropriate and back-translated to ensure accuracy, co-ordinated by the lead national 
collaborator.  
 
Each centre could access our survey website to review local progress, and generate 
local login cards for their participants. A Centre Management Report allowed the local 
investigator to see when a patient had completed the questionnaire and also to see 
the details they had provided for their GP and specialist, to invite those professionals 
to take part.  
 
Statistical analysis 
Descriptive statistics were used to assess the questionnaires completed. Where 
appropriate this included reporting the number of missing responses for each 
question. Questionnaire responses were compared between pairs of responders (e.g. 
patient and GP) and agreement assessed by the Kappa statistic.  
 
Time differences in the patient pathway between key events were calculated from the 
dates provided by the patients. We calculated the difference between 1) first 
symptoms and GP appointment, 2) first symptoms and appointment with a specialist, 
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3) first symptoms and cancer diagnosis, 4) GP appointment and appointment with 
specialists, 5) GP appointment and cancer diagnosis. Patient pathway times were 
reported by median and interquartile range (IQR) 
 
We compared responses by country for those with the highest number of responders 
(England, Italy versus Others including France, Denmark and Hungary). Comparison 
of responses between subgroups (such as age group or tumour type) were not 
appropriate due to the pilot aims and small sample. 
 
Results 
Study approval  
Initially 7 UK departments expressed interest in the study from 4 treatment centres 
(Leeds x2, Sheffield x2, Birmingham x2 and London) and 13 EU Centres in 5 countries 
(Italy, France x5, Spain x5, Hungary and Denmark). Swedish and German centres 
then could not proceed without funding for ethics and an employee to deliver the 
project. The timeliness of study opening varied by over 12 months, and it was not 
always possible to open the study due to available resources (Figure 1).  
 
Data 
A total of 9 centres in 5 countries participated; responses for each are shown in table 
1. A total of 68 patients, 42 GPs and 50 specialist centres completed their respective 
questionnaires. Responses for all three elements (patient, GP and specialist centre) 
were completed by 32. While the greatest number of patient responses were 
completed in England, the other countries, in particular Italy, were more successful in 
obtaining responses for all three responder types.  
12 
12 
 
A wide range of symptoms were reported by patients and GPs, with more symptoms 
reported by patients (table 2). The most commonly reported symptoms by the patients 
were: swelling or lump with no pain (31%), bone pain (31%), tiredness (26%), swelling 
or lump with pain (18%). Swelling or lump with pain was the most commonly reported 
symptom by the GP (31%) followed by bone pain (24%).  
 
Almost 50% of patients reported seeing their GP between 1 and 4 weeks from first 
symptoms, and 18% reported waiting more than 1 month with symptoms before 
contacting a GP. However, 47% of GPs reported that the patients waited more than 1 
month with symptoms before contacting them (Table 3). Overall 39% of patients 
reported visiting their GP twice or more before diagnosis (table 5). This was different 
between countries; 47% in England, 34% in Italy and 35% in the other countries 
combined, but not statistically significantly (p=0.44). The use of emergency hospital 
services (accident and emergency departments) was low, and consistent between 
reporters. Referrals direct to cancer specialist teams were uncommon, being more 
often into a non-specialist hospital doctor and then onward referral to 
oncology/haematology. 
 
Within the limitations of our pilot design, we observed shorter median times from 
symptom onset to specialist appointment and from symptoms to diagnosis in Italy than 
in the other nations studied and the longest in the UK (see Supplementary table 1).  
  
Triangulating the data, there was inconsistency of reporting of the diagnostic process 
(table 4).  Two thirds of patients reported initially seeing a GP about symptoms and 
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21% reported attending emergency services. A third of GPs reported making an urgent 
referral for assessment of cancer, while only 14% of specialist centres reported 
receiving a referral from a GP.   
 
Patients reported a wide range of times between key points on the patient pathway 
(figure 3). The median time between patients reporting symptoms and seeing a 
specialist was 59 days (IQR 31 to 130 days). However, patients were then promptly 
diagnosed after seeing a specialist with the median time from symptoms to cancer 
diagnosis 63 days (IQR 35 to 153 days). Where data on time from symptoms to 
diagnosis were present from several sources (in 18 patients), the reported time 
differences were modest; mostly under 14 days and never over 30 days. For all time 
periods there were some patients with extended times on the diagnostic pathway.  
 
Discussion  
In this feasibility pilot study, we have demonstrated that international multi-
professional research, including patients as direct data contributors in TYA with 
cancer, is feasible within our international collaborative network. Conducting such 
research without grant funding was difficult. Responses from primary care were the 
most difficult to obtain, but not impossible and not uniformly obtained by country. The 
results observed for patient experience must be interpreted with caution given our pilot 
aims and sample size.  
There were significant variations and barriers presented by regulatory aspects. 
Translation of study forms significantly delayed study implementation. Administrative 
burdens upon the study team and investigators varied across locations within Europe, 
despite local research teams being highly motivated to participate. Imbalances 
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between available research resource and local governance requirements resulted in 
inequity in our ability to open the study in a timely manner, or to open it at all in some 
places. Explicit unified European positions on these issues for relatively low-risk 
questionnaire-based studies could substantially improve research productivity. We 
recommend proportionate review systems for defined low risk projects are considered 
internationally according to local systems [35].  
Although our pilot study had limited sample size, the findings are broadly comparable 
with other studies. We found approximately 40% of patients visited their GP at least 
twice prior to diagnosis. In comparison, a large UK primary care cohort study, in the 3 
months before diagnosis 42.9% of TYA with cancer consulted primary care  times 
vs 11.5% in age-matched patients without a cancer diagnosis [27]. Almost twice as 
many TYA visited their GP more than 3 times before diagnosis of cancer than is 
observed in older adults (38% versus 20%) [28]. We found the median time from 
reporting symptoms to cancer diagnosis was 9 weeks. In comparison a 2007 study 
[36] showed a median time from symptom onset to diagnosis of 9.5 weeks (range 2±
191.5 weeks). We identified marked differences in the proportion of repeated visits 
reported by GPs and patients. A survey of 174 TYA patients in 2004 showed that 20% 
of patients waited several months before seeking help after experiencing symptoms 
and that 71% of TYAs also reported visiting their GP 2-5 times before being referred 
to a specialist [37]. Some of the reasons given for this delay included; being scared to 
seek help, ignoring symptoms, concerned or embarrassed about symptoms,  not 
having time, concerns about not being taken seriously and fear of bad news [36, 37].  
Symptoms reported were distinct between primary care and patients, despite data 
collection being shortly after diagnosis. It is possible primary care recorded only the 
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most clinically worrying symptom. Pain was a common feature of primary care 
SK\VLFLDQV¶ reported symptoms, although patients commonly reported painless lumps. 
The range in times from onset of symptoms to diagnosis in our study are very wide, 
while the median times are reasonable clinically for the cancers being considered. 
This asymmetric and skewed distribution may indicate a sporadic not a systematic 
prolongation of the process. This is reflected in the recent µWKUHH-OHJJHG¶ approach to 
health service improvement in Denmark [38, 39].  The characteristics and risk factors 
associated with this could be examined in a larger study, focusing upon the cancers 
where data most strongly indicates a prolonged pathway is detrimental [40]. In the UK 
campaigns designed to increase awareness of the signs and symptoms of TYA 
cancers have been implemented [41].   
 
There are obvious limitations of this study; it was not intended as a comprehensively 
sampled inception cohort design, included recruitment only at selected centres with 
small sample size. Eligibility only shortly after diagnosis may have limited recruitment. 
The study clearly requires extension before firm conclusions can be reached. 
However, we met our main pilot study objectives; we demonstrated the feasibility of 
such studies which cross traditional data-reporting approaches, including the 
collection of triangulated data. There are preliminary signals of possible differences in 
these patient pathways internationally which merit confirmation as well as exploration 
of mechanisms in future work. The study also indicated some key methodological 
learning for more definitive future studies; patients reported a larger burden of 
symptoms than GPs. However SDWLHQW¶V symptoms were reported from a check list, 
whereas GPs reported symptoms via a free text field, and GP records may well only 
include key symptoms even when free text is available. The evolution in the perception 
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of events over time is apparent, with patients reporting primary care consultations at 
the outset of their pathways but their oncology specialists not identifying this from their 
records. Precise recording of the relation between the date of events and of data 
collection may be very important in conducting future larger-scale studies. The 
proportion reporting a shorter symptom duration was higher for patients than it was by 
GPs. This may be important when measuring this in future studies. Triangulating the 
responses from patients, primary care and secondary care clinicians about how 
symptoms were investigated through health services via various emergency and 
elective providers requires the development of a clear shared terminology.   
The importance on international networking (as demonstrated by this study) is clear in 
driving and delivering such a study, and the ability of a network such as ENTYAC to 
increase our understanding and potentially reduce diagnostic delay is apparent [42]. 
Our group plan to take this learning forward in building multi-centre European studies 
for TYA with cancer in this and other areas of enquiry 
It is interesting to note from the current literature the influence that the initial clinical 
impression or extent of µcancer suspicion¶ of the initially assessing GP has upon the 
subsequent pathway. This impression may be due to the presence of non-specific 
symptoms (such as lump without pain) at that assessment. However, many cancers 
present without specific symptoms, particularly while of early stage, and this may be 
unduly influencing clinical behaviour [43]. This is particularly relevant to TYA. As TYA 
have less experience of medical encounters and greater embarrassment when 
reporting symptoms, the proportion giving non-specific descriptions may be increased 
[44, 45].  If this is coupled with a low clinical suspicion (driven by the epidemiology), 
long delays would then occur for cancers where non-specific symptoms are reported.  
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In future we propose to focus upon the experiences of TYA patients with very long 
times to diagnosis, specifically where time from symptoms to diagnosis appears to 
markedly influence clinical outcome; non-rhabdomyosarcoma soft tissue sarcoma, 
and advanced germ cell tumour [41]. Analyses by cancer type were not possible in 
our sample size, nor appropriate in a pilot design. Very long diagnostic pathways may 
be clinically important and costly to healthcare resources, but moreover are highly 
emotive for patients, carers and clinicians, and may promote a clinical impression that 
all pathways are more prolonged than they generally are.  
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Figure 1: A timeline for the opening of the pilot study, in successful and other 
initially interested centres  
 
 19 
Figure 2: Patient reported pathway times (median and IQR)  
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Table 1: Responses by country 
Country No. of 
centres 
Patient 
responses 
GP 
responses 
Centre 
responses 
All 3 
responses 
England 3 30 12 14 4 
France 3 9 7 9 7 
Italy 1 21 16 20 15 
Denmark 1 4 4 4 4 
Hungary  1 4 3 3 2 
Total 9 68 42 50 32 
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Table 2: Patient and GP reported frequent symptoms  
 Patient (N=68) GP (N=42) 
Symptom n % N % 
Swelling/lump with no pain 21 31 6 14 
Bone pain 21 31 10 24 
Tiredness  18 26 4 10 
Swelling/lump with pain 12 18 13 31 
Weight loss 9 13   
Abdominal pain 9 13 2 5 
Breathlessness 8 12 1 2 
Night sweats 5 7   
Cough  5 7 4 10 
Sweats  4 6   
Feeling sick  4 6   
Headaches 4 6 2 5 
Poor balance 4 6 3 7 
Reduced movement 4 6   
Other* 39 50 11 25 
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*Other included: Drowsiness, Enlarged lymph nodes, Uncoordinated walking, Loss of 
vision or double vision, High temperature, Irregular periods, Itching, Bruising, Enlarged 
spleen, Fever, Infection, Diarrhoea, Difficulty swallowing, Numbness, Problems with 
writing or doing calculations, Recurrent infections, Seizures, Broken bones, Changes 
in personality and intellect, Vomiting, Weight gain 
 
 
Table 3: Symptom duration (time from first symptoms to contacting GP), patient 
and GP reported 
 Patient (N=68) GP (N=42) 
Symptom duration n % n % 
Less than 1 week 14 21 3 7 
1-4 weeks 33 48 16 38 
5-7 weeks 3 4 6 14 
2-5 months 5 7 9 21 
6-12 months 3 4 3 7 
More than 12 months 2 3 2 5 
N/A or no symptoms (e.g. screen detected) 5 7 3 7 
Missing  3 4   
 
 23 
35 with both patient and GP reported duration: Kappa agreement = 46% (moderate 
agreement) 
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Table 4: Pathway and referral process, patient, GP and centre reported 
outcomes  
 n % 
Patient UHVSRQVH N=68  
I had symptoms/I noticed a bodily change and went to see a doctor 
(GP) 
41 60 
I had symptoms/I noticed a bodily change as went/was taken to 
Accident and Emergency (A&E) 
6 9 
I had seen a doctor/GP with symptoms, but went/was taken to A&E 
when things worsened 
8 12 
I was being investigated by my doctor for another problem during 
which time the cancer was discovered 
7 10 
Other  2 3 
Missing  4 6 
GP responses  N=42  
Emergency admission: a referral to A&E for immediate admission 6 14 
An urgent referral for assessment of cancer symptoms/signs/test 
results 
14 33 
A less urgent referral in which cancer is raised as a possibility 2 5 
 25 
A more general referral for investigation and assessment without 
cancer mentioned  
7 17 
No referral was made 4 10 
Other  5 12 
Missing  4 10 
Centre responses  N=50  
GP referral 7 14 
Medical specialist/consultant referral; 23 46 
Referral from another hospital outpatient clinic 12 24 
Other  7 14 
Missing  1 2 
 
Patient question: Which of the following best describes the events which led to your 
diagnosis of cancer? 
GP question: If you made a referral to specialist services, which of the following 
best describes the nature of this referral? 
Centre question: How was the patient referred to the hospital/specialist services 
related to their cancer? 
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Table 5: Number of times contacted GP before diagnosis, patient reported 
response overall and by country 
 All (N=68) England 
(n=30) 
Italy (n=21) Other Q  
 n % n % n % n % 
0 8 12 3 10 2 10 3 18 
1 25 37 7 23 10 48 8 47 
2-3 22 32 11 37 6 29 5 29 
4+ 5 7 3 10 1 5 1 6 
Missing  8 12 6 20 2 10   
 
 Other includes Denmark, France and Hungary  
 
 
  
 27 
References 
1. Lewis, I.J., Cancer in adolescence. Br Med Bull, 1996. 52(4): p. 887-97. 
2. Stark, D. and I. Lewis, Improving outcomes for teenagers and young adults (TYA) with cancer. 
Klin Padiatr, 2013. 225(6): p. 331-4. 
3. Brierley, R., Holmes, D., Ceschia, A., Jouret, J., Teenage Cancer Trust: pursuing equality. 
Lancet Oncology, 2009. 10(5): p. 455-8. 
4. Gatta, G., et al., Survival of European children and young adults with cancer diagnosed 1995-
2002. Eur J Cancer, 2009. 45(6): p. 992-1005. 
5. Trama, A., et al., Survival of European adolescents and young adults diagnosed with cancer in 
2000-07: population-based data from EUROCARE-5. Lancet Oncol, 2016. 17(7): p. 896-906. 
6. Aben, K.K., et al., Cancer in adolescents and young adults (15-29 years): a population-based 
study in the Netherlands 1989-2009. Acta Oncol, 2012. 51(7): p. 922-33. 
7. Desandes, E. and D.P. Stark, Epidemiology of Adolescents and Young Adults with Cancer in 
Europe. Prog Tumor Res, 2016. 43:1-15.(doi): p. 10.1159/000447037. Epub 2016 Sep 5. 
8. O'Hara, C., et al., Trends in survival for teenagers and young adults with cancer in the UK 
1992-2006. Eur J Cancer, 2015. 
9. Stark, D., et al., Survival patterns in teenagers and young adults with cancer in the United 
Kingdom: Comparisons with younger and older age groups. Eur J Cancer, 2015. 
10. Bielack, S.S., et al., Bone tumors in adolescents and young adults. Curr Treat Options Oncol, 
2008. 9(1): p. 67-80. 
11. Bleyer, A., et al., Relative lack of conditional survival improvement in young adults with 
cancer. Semin Oncol, 2009. 36(5): p. 460-7. 
12. CRUK. Teenage and young adult cancer statistics. 2013  13-05-2013]. 
13. Ferrari, A., et al., Starting an adolescent and young adult program: some success stories and 
some obstacles to overcome. J Clin Oncol, 2010. 28(32): p. 4850-7. 
14. Birch, J.M., et al., Survival from cancer in teenagers and young adults in England, 1979-2003. 
Br J Cancer, 2008. 99(5): p. 830-5. 
15. De Angelis, R., et al., Cancer survival in Europe 1999ʹ2007 by country and age: results of 
EUROCARE-5Ͷa population-based study. The lancet oncology, 2014. 15(1): p. 23-34. 
16. Bleyer, A. and R. Barr, Cancer in young adults 20 to 39 years of age: overview. Semin Oncol, 
2009. 36(3): p. 194-206. 
17. Albritton, K.H. and T. Eden, Access to care. Pediatric blood & cancer, 2008. 50(S5): p. 1094-
1098. 
18. ĂŶŐͲdĂŶ͕ T. and E.L. Franco, Diagnosis delays in childhood cancer. Cancer, 2007. 110(4): p. 
703-713. 
19. Fern, L.A., et al., How frequently do young people with potential cancer symptoms present in 
primary care? British Journal of General Practice, 2011. 61(586): p. e223-e230. 
20. Goyal, S., et al., Symptom interval in young people with bone cancer. Eur J Cancer, 2004. 
40(15): p. 2280-6. 
21. Martin, S., et al., Delays in cancer diagnosis in underinsured young adults and older 
adolescents. Oncologist, 2007. 12(7): p. 816-24. 
22. Desandes, E., et al., Pathways of care for adolescent patients with cancer in France from 
2006 to 2007. Pediatr Blood Cancer, 2012. 58(6): p. 924-9. 
23. Veneroni, L., et al., Symptom interval in pediatric patients with solid tumors: adolescents are 
at greater risk of late diagnosis. Pediatr Blood Cancer, 2013. 60(4): p. 605-10. 
24. Klein-Geltink, J., et al., Impact of age and diagnosis on waiting times between important 
healthcare events among children 0 to 19 years cared for in pediatric units: the Canadian 
Childhood Cancer Surveillance and Control Program. Journal of pediatric 
hematology/oncology, 2006. 28(7): p. 433-439. 
 28 
25. Coccia, P.F., et al., Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical 
Practice Guidelines in Oncology. J Natl Compr Canc Netw., 2018. 16(1): p. 66-97. doi: 
10.6004/jnccn.2018.0001. 
26. Bleyer, A., The adolescent and young adult gap in cancer care and outcome. Curr Probl 
Pediatr Adolesc Health Care, 2005. 35(5): p. 182-217. 
27. Dommett, R., et al., Features of cancer in teenagers and young adults in primary care: a 
population-based nested caseʹcontrol study. Br J Cancer, 2013. 108(11): p. 2329-2333. 
28. Furness, C.L., et al., Cancer Patient Experience in the Teenage Young Adult Population- Key 
Issues and Trends Over Time: An Analysis of the United Kingdom National Cancer Patient 
Experience Surveys 2010-2014. J Adolesc Young Adult Oncol., 2017. 6(3): p. 450-458. doi: 
10.1089/jayao.2016.0058. Epub 2017 May 19. 
29. Lethaby, C.D., et al., A systematic review of time to diagnosis in children and young adults 
with cancer. Arch Dis Child., 2013. 98(5): p. 349-55. doi: 10.1136/archdischild-2012-303034. 
Epub 2013 Mar 9. 
30. Launay, E., et al., Inadequate critical appraisal of studies in systematic reviews of time to 
diagnosis. J Clin Epidemiol., 2016. 78:43-51.(doi): p. 10.1016/j.jclinepi.2016.03.013. Epub 
2016 Mar 30. 
31. Weller, D., et al., The Aarhus statement: improving design and reporting of studies on early 
cancer diagnosis. Br J Cancer, 2012. 106(7): p. 1262-1267. 
32. Coleman, M.P., et al., Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and 
the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of 
population-based cancer registry data. Lancet, 2011. 377(9760): p. 127-38. 
33. Weller, D., et al., An investigation of routes to cancer diagnosis in 10 international 
jurisdictions, as part of the International Cancer Benchmarking Partnership: survey 
development and implementation. BMJ Open., 2016. 6(7): p. e009641. doi: 
10.1136/bmjopen-2015-009641. 
34. Gatta, G., et al., Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer., 
2011. 47(17): p. 2493-511. doi: 10.1016/j.ejca.2011.08.008. Epub 2011 Oct 25. 
35. NHS Health Research Authority. Proportionate Review Information and Guidance for 
Applicants. https://www.hra.nhs.uk/documents/1022/proportionate-review-information-
guidance-document.pdf. 2018 [Accessed 15th May 2018]. 
36. Eden, T., et al. Symptom interval (SI) in teenagers and young adults (TYA) with cancer. in 
Pediatric blood & cancer. 2007. WILEY-LISS DIV JOHN WILEY & SONS INC, 111 RIVER ST, 
HOBOKEN, NJ 07030 USA. 
37. Smith, S., et al., The experiences of teenagers and young adults with cancerͶresults of 2004 
conference survey. European Journal of Oncology Nursing, 2007. 11(4): p. 362-368. 
38. Jensen, H., M.L. Torring, and P. Vedsted, Prognostic consequences of implementing cancer 
patient pathways in Denmark: a comparative cohort study of symptomatic cancer patients in 
primary care. BMC Cancer., 2017. 17(1): p. 627. doi: 10.1186/s12885-017-3623-8. 
39. Vedsted, P. and F. Olesen, A differentiated approach to referrals from general practice to 
support early cancer diagnosis - the Danish three-legged strategy. Br J Cancer., 2015. 
112(Suppl 1): p. S65-9. doi: 10.1038/bjc.2015.44. 
40. Ferrari, A., et al., The Sooner the Better? How Symptom Interval Correlates With Outcome in 
Children and Adolescents With Solid Tumors: Regression Tree Analysis of the Findings of a 
Prospective Study. Pediatric Blood & Cancer, 2016. 63(3): p. 479-85. 
41. Kyle, R.G., et al., Increased cancer awareness among British adolescents after a school-based 
educational intervention: a controlled before-and-after study with 6-month follow-up. BMC 
Public Health, 2013. 13(1): p. 190. 
42. Stark, D., et al., Teenagers and young adults with cancer in Europe: from national 
programmes to a European integrated coordinated project. Eur J Cancer Care (Engl), 2015. 
 29 
43. Jensen, H., et al., Cancer suspicion in general practice, urgent referral and time to diagnosis: 
a population-based GP survey and registry study. BMC Cancer, 2014. 14: p. 636. 
44. Fern, L.A., et al., Why can't we improve the timeliness of cancer diagnosis in children, 
teenagers, and young adults? BMJ, 2013. 347: p. f6493. 
45. Fern, L.A., et al., How frequently do young people with potential cancer symptoms present in 
primary care? Br J Gen Pract, 2011. 61(586): p. e223-30. 
 
 
 30 
 
